PAVM Stock Risk & Deep Value Analysis
PAVmed Inc
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About PAVM Stock
We analyzed PAVmed Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PAVM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
Get notified when PAVM moves
Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.
📈PAVM Performance Overview3yr weekly
Unlock PAVM Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
PAVM Risk Analysis & Red Flags
What Could Go Wrong
PAVmed Inc. faces immediate and critical financial risk with only $6.5 million in cash against quarterly operating expenses of $8.1 million as of Q1 2026. Failure to secure substantial new funding for the parent company within the next 1-2 months will lead to a severe liquidity crisis, potentially forcing a fire sale of assets or substantial, value-destroying dilution for common shareholders.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
Medium
Red Flags
- ⚠
PAVmed Inc. consolidated cash balance of $6.5 million as of Q1 2026 vs. $8.1 million in quarterly operating expenses, indicating a cash runway of less than one quarter.
- ⚠
Persistent high cash burn rate at the parent company without meaningful offsetting revenue generation.
- ⚠
High likelihood of significant future shareholder dilution for PAVmed Inc. common stock, given ongoing funding needs and past S-3 filings.
Upcoming Risk Events
- 📅
PAVmed Inc. Failure to Secure Funding (Q2/Q3 2026): Inability to raise sufficient capital for parent operations, leading to severe liquidity crisis and potential bankruptcy or massive dilution.
- 📅
Veris Health Regulatory Delays (Q4 2026+): Prolonged delays in receiving FDA 510(k) clearance for the implantable cardiac monitor, pushing back commercialization timeline.
- 📅
Slower-than-expected EsoGuard Commercialization (Ongoing): If quarterly test volumes or revenue growth for EsoGuard decelerates or fails to meet internal targets.
When to Reconsider
- 🚪
Exit if PAVmed Inc.'s consolidated cash balance drops below $5 million without an announced financing round.
- 🚪
Sell if Lucid Diagnostics' EsoGuard quarterly test volume declines year-over-year or quarter-over-quarter for two consecutive quarters.
- 🚪
Exit if Veris Health's FDA 510(k) clearance is delayed beyond Q1 2027 with no clear path forward.
Unlock PAVM Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does PAVmed Inc (PAVM) Do?
Market Cap
$45.75M
Sector
Healthcare
Industry
Medical Devices
Employees
39
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York
Visit PAVmed Inc WebsiteInvestment Thesis
If PAVmed Inc. successfully secures near-term financing for its parent operations (e.g., $30M+ by Q3 2026) and Lucid Diagnostics significantly accelerates EsoGuard commercialization (e.g., reaching $5M+ quarterly revenue by Q4 2026 with expanding reimbursement) alongside Veris Health achieving FDA 510(k) clearance in late 2026, then the combined entity could see its market capitalization re-rate significantly, as these milestones de-risk the speculative investment and validate future market leadership in early cancer detection and remote health monitoring.
Is PAVM Stock Undervalued?
Unlock the full AI analysis for PAVM
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PAVM Price Targets & Strategy
12-Month Target
$10.00
Bull Case
$40.50
Bear Case
$1.00
Valuation Basis
Implied $0.08B market cap (1.6x current) reflecting anticipated near-term dilution, successful capital raise, and early commercial traction for EsoGuard, heavily discounting future growth and dilution.
Entry Strategy
Highly speculative. Consider small allocation only on confirmation of successful capital raise, or on a dip below $5 if accompanied by positive operational news from Lucid or Veris.
Exit Strategy
Take profit on any major spikes above $15-20 following significant operational milestones (e.g., Veris FDA clearance). Stop-loss below $4.50 if liquidity concerns persist or dilution is more severe than anticipated.
Portfolio Allocation
1-3% for aggressive risk tolerance only. Not suitable for moderate or conservative portfolios.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is PAVM Financially Healthy?
Valuation
P/E Ratio
114.08
Profitability
Gross Margin
-205.63%
Operating Margin
-30797.18%
Net Margin
564.79%
Return on Equity
1.02%
Revenue Growth
-97.63%
EPS
$-17.84
Balance Sheet
Current Ratio
0.17
Quick Ratio
0.15
Debt/Equity
0.33
Cash & Equivalents
$6.50M
Other
Beta (Volatility)
0.61
Does PAVM Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Expanding
Moat Sources
1 Identified
The nascent moat, primarily derived from EsoGuard's patented technology and FDA clearances, is fragile. Its durability hinges on widespread clinical adoption, favorable reimbursement, and continued commercial execution before competitors can introduce superior or equivalent alternatives.
Moat Erosion Risks
- •Development of competing diagnostic technologies with greater accuracy or lower cost.
- •Slow market adoption or lack of robust insurance reimbursement for EsoGuard.
- •Failure to secure additional intellectual property protections for pipeline products like Veris Health.
PAVM Competitive Moat Analysis
Sign up to see competitive advantages
PAVM Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. High-risk small-cap attracting speculative interest but also significant skepticism due to financial health.
Institutional Sentiment
Positive, but with low conviction due to limited coverage. Average target of $40.50 from 2 analysts is highly bullish, but based on a small sample size.
Insider Activity (Form 4)
No specific Form 4 insider transactions were provided in the supplied sources for the last 90 days.
Options Flow
Normal options activity; no specific unusual activity provided in the supplied sources.
Earnings Intelligence
Next Earnings
Estimated early-August 2026 (for Q2 2026)
Surprise Probability
Low. Highly dependent on achieving aggressive commercial ramp for EsoGuard and securing critical financing for PAVmed.
Historical Earnings Pattern
Insufficient historical data to determine a consistent stock price reaction pattern to earnings reports.
Key Metrics to Watch
Competitive Position
Top Competitor
Exact Sciences (EXAS)
Market Share Trend
Gaining (for EsoGuard, from a very low base), N/A for PAVmed consolidated.
Valuation vs Peers
PAVmed Inc. is largely pre-revenue at the consolidated level and significantly smaller, making direct valuation comparisons difficult. It trades at an implied substantial premium on future growth potential compared to established diagnostics peers like Exact Sciences, which generate significant revenue and cash flow, reflecting the high-risk, high-reward nature.
Competitive Advantages
- •Proprietary technology and intellectual property for EsoGuard and EsoCheck devices for Barrett's Esophagus screening.
- •FDA clearances and regulatory pathways established for EsoGuard.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive PAVM Stock Higher?
Near-Term (0-6 months)
- •PAVmed Inc. Capital Raise (Q2/Q3 2026): Successful completion of a significant financing round (e.g., $30M+) to provide 4-6 quarters of operating capital for the parent company.
- •Lucid Diagnostics Q2 2026 Earnings (est. August 2026): Exceeding 4,500 EsoGuard tests processed and $1.8M in revenue, signaling sustained commercial acceleration.
Medium-Term (6-18 months)
- •Veris Health FDA 510(k) Clearance (Late 2026): Approval for its implantable cardiac monitor, enabling market entry and initial sales in Q1 2027.
- •Lucid Diagnostics Major Reimbursement Expansion (H1 2027): Securing coverage from a major private insurer or significant expansion of Medicare coverage, driving broader market access for EsoGuard.
Long-Term (18+ months)
- •EsoGuard Market Leadership (2028-2029): Capturing >20% market share in Barrett's Esophagus screening, driving $150M+ annual revenue run-rate for Lucid.
- •Veris Health Widespread Adoption (2029-2030): Achieving significant penetration in remote cardiac monitoring, contributing $100M+ in annual revenue and establishing a recurring revenue base.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for PAVM?
- ✓
Watch PAVmed Inc.'s consolidated cash balance: any decline below $5M without announced financing is a critical negative signal.
- ✓
Monitor Lucid Diagnostics' EsoGuard quarterly test volume: sustained growth exceeding 35% QoQ signals strong commercial traction.
- ✓
Track Veris Health's FDA 510(k) clearance timeline: any delay beyond Q1 2027 would impact future revenue streams.
Bull Case Analysis
Sign up free to see the bull case
Competing with PAVM
See how PAVmed Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
PAVmed Inc PAVM | $45.7M | 1.8 | 114.1 | $22,000 | 564.8% | -97.6% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How PAVmed Inc Makes Money
PAVmed Inc. is a medical technology company focused on developing and commercializing innovative medical devices and diagnostics. Its primary value resides in its majority-owned subsidiary, Lucid Diagnostics, which offers EsoGuard, a DNA test for the early detection of esophageal precancer (Barrett's Esophagus) using the EsoCheck capsule-based sample collection device. PAVmed also has Veris Health, which is developing implantable cardiac monitors for remote patient monitoring. The company aims to generate revenue through the sale of EsoGuard tests and, in the future, Veris Health devices and associated services.
Read Full Business Model BreakdownFAQ
What is the DVR Score for PAVmed Inc (PAVM)?
As of May 25, 2026, PAVmed Inc has a DVR Score of 1.8 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of PAVmed Inc?
PAVmed Inc's market capitalization is approximately $45.7M. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does PAVmed Inc use?
PAVM is the ticker symbol for PAVmed Inc. The company trades on the NCM.
What is the risk level for PAVM stock?
Our analysis rates PAVmed Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of PAVM?
PAVmed Inc currently has a price-to-earnings (P/E) ratio of 114.1. This is above the market average, suggesting the stock may be priced for high growth expectations.
Is PAVmed Inc's revenue growing?
PAVmed Inc has reported revenue growth of -97.6%. Revenue has been declining, which warrants closer examination.
Is PAVM stock profitable?
PAVmed Inc has a profit margin of 564.8%. This indicates strong profitability.
How often is the PAVM DVR analysis updated?
Our AI-powered analysis of PAVmed Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 25, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PAVM (PAVmed Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.